2022-05-23 Top Buy Stocks

PDC Energy, Inc., an independent exploration and production company, acquires, explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the United States. The company’s operations are primarily located in the Wattenberg Field in Colorado and the Delaware Basin in Texas. As of December 31, 2021, it owned interests in approximately 3,500 productive gross wells. The company was formerly known as Petroleum Development Corporation and changed its name to PDC Energy, Inc. in June 2012. PDC Energy, Inc. was founded in 1969 and is headquartered in Denver, Colorado.

On May 06, 2022, the compnay has completed its acquisition of Great Western Petroleum, LLC (“Great Western”), a privately held company based in Denver. The consideration paid was $543 million (less $50 million previously placed into escrow) and approximately 4 million shares of PDC common stock.

For its 2022 first quarter, the company reported Net cash from operating activities of approximately $489 million. Approximately $319 million of adjusted free cash flow, a non-U.S. GAAP metric defined below. Total production of 17.9 million barrels of oil equivalent or approximately 199,000 Boe per day and oil production of 5.9 million barrels or approximately 65,000 Bbls per day.

PDCE receives outperform rating in price to bookvalue and discounted cash flow. Technical indicators signal the bullish signs, as there is a bullish crossover in the Stochastic oscillator, the MACD is trying to cross back up and the RSI stands at 47.1 with positive bias. We rate PDC Energy, Inc. (PDCE) a BUY.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

The company reported that cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipeline. Research highlighting novel reprogramming technologies designed to overcome barriers to successful adoptive cell therapy in solid tumors presented at multiple scientific conferences.

The company reported a net loss of $68.1 million for the first quarter ended March 31, 2022, compared to a net loss of $55.0 million for the same period in 2021. Research and development (R&D) expenses were $35.8 million for the first quarter ended March 31, 2022, compared to $41.5 million for the same period in 2021.

LYEL receives outperform rating in price to bookvalue and discounted cash flow. Technical indicators signal the bullish signs, as there is a bullish crossover in the Stochastic oscillator, the MACD is trying to cross back up and the RSI stands at 37.7 with positive bias. We rate Lyell Immunopharma, Inc. (LYEL) a BUY.